FR2707664B1 - Vecteurs viraux et utilisation en thérapie génique. - Google Patents

Vecteurs viraux et utilisation en thérapie génique.

Info

Publication number
FR2707664B1
FR2707664B1 FR9308596A FR9308596A FR2707664B1 FR 2707664 B1 FR2707664 B1 FR 2707664B1 FR 9308596 A FR9308596 A FR 9308596A FR 9308596 A FR9308596 A FR 9308596A FR 2707664 B1 FR2707664 B1 FR 2707664B1
Authority
FR
France
Prior art keywords
gene therapy
viral vectors
viral
vectors
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9308596A
Other languages
English (en)
Other versions
FR2707664A1 (fr
Inventor
Perricaudet Michel
Vigne Emmanuelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9308596A priority Critical patent/FR2707664B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR) filed Critical Centre National de la Recherche Scientifique CNRS
Priority to SK312-95A priority patent/SK282843B6/sk
Priority to AU72646/94A priority patent/AU7264694A/en
Priority to CN94190594A priority patent/CN1115414C/zh
Priority to BR9405507A priority patent/BR9405507A/pt
Priority to KR1019950700975A priority patent/KR100356615B1/ko
Priority to ES94922889T priority patent/ES2310924T3/es
Priority to DK94922889T priority patent/DK0667912T3/da
Priority to AT94922889T priority patent/ATE399873T1/de
Priority to PCT/FR1994/000851 priority patent/WO1995002697A1/fr
Priority to CZ1995639A priority patent/CZ287157B6/cs
Priority to JP50436895A priority patent/JP4190028B2/ja
Priority to PT94922889T priority patent/PT667912E/pt
Priority to HU9500732A priority patent/HU216871B/hu
Priority to NZ269156A priority patent/NZ269156A/en
Priority to EP94922889A priority patent/EP0667912B1/fr
Priority to RU95108217/13A priority patent/RU2219241C2/ru
Priority to PL94308122A priority patent/PL179877B1/pl
Priority to CA002144040A priority patent/CA2144040A1/fr
Priority to DE69435108T priority patent/DE69435108D1/de
Priority to IL11028494A priority patent/IL110284A0/xx
Priority to ZA945012A priority patent/ZA945012B/xx
Priority to UA95038233A priority patent/UA65516C2/uk
Publication of FR2707664A1 publication Critical patent/FR2707664A1/fr
Priority to NO19950939A priority patent/NO321309B1/no
Priority to FI951138A priority patent/FI951138A/fi
Publication of FR2707664B1 publication Critical patent/FR2707664B1/fr
Application granted granted Critical
Priority to US10/301,085 priority patent/US20030096787A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9308596A 1993-07-13 1993-07-13 Vecteurs viraux et utilisation en thérapie génique. Expired - Fee Related FR2707664B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR9308596A FR2707664B1 (fr) 1993-07-13 1993-07-13 Vecteurs viraux et utilisation en thérapie génique.
RU95108217/13A RU2219241C2 (ru) 1993-07-13 1994-07-08 Дефектный рекомбинантный аденовирусный вектор (варианты)
AU72646/94A AU7264694A (en) 1993-07-13 1994-07-08 Defective adenovirus vectors and use thereof in gene therapy
BR9405507A BR9405507A (pt) 1993-07-13 1994-07-08 Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
KR1019950700975A KR100356615B1 (ko) 1993-07-13 1994-07-08 결함아데노바이러스벡터및유전자치료에서그의사용
ES94922889T ES2310924T3 (es) 1993-07-13 1994-07-08 Vectores adenovirales defectivos y utilizacion en terapia genica.
DK94922889T DK0667912T3 (da) 1993-07-13 1994-07-08 Defekte adenovirusvektorer og anvendelse heraf i genterapi
AT94922889T ATE399873T1 (de) 1993-07-13 1994-07-08 Defekte adenovirus-vektoren und deren verwendung in der gentherapie
PCT/FR1994/000851 WO1995002697A1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique
CZ1995639A CZ287157B6 (en) 1993-07-13 1994-07-08 Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
JP50436895A JP4190028B2 (ja) 1993-07-13 1994-07-08 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用
PT94922889T PT667912E (pt) 1993-07-13 1994-07-08 Vectores adenovirais deficientes e utilização em terapia génica
HU9500732A HU216871B (hu) 1993-07-13 1994-07-08 Defektív adenovírusvektorok és génterápiai alkalmazásuk
NZ269156A NZ269156A (en) 1993-07-13 1994-07-08 Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
SK312-95A SK282843B6 (sk) 1993-07-13 1994-07-08 Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
CN94190594A CN1115414C (zh) 1993-07-13 1994-07-08 用于基因治疗的病毒载体
PL94308122A PL179877B1 (pl) 1993-07-13 1994-07-08 Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
CA002144040A CA2144040A1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique
DE69435108T DE69435108D1 (de) 1993-07-13 1994-07-08 Defekte adenovirus-vektoren und deren verwendung in der gentherapie
EP94922889A EP0667912B1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique
IL11028494A IL110284A0 (en) 1993-07-13 1994-07-11 Viral vectors and their use in gene therapy
ZA945012A ZA945012B (en) 1993-07-13 1994-07-11 Viral vectors and their use in gene therapy
UA95038233A UA65516C2 (en) 1993-07-13 1994-08-07 Defect adenovirus-derived vectors and the use thereof in gene therapy
NO19950939A NO321309B1 (no) 1993-07-13 1995-03-10 Defektive, rekombinante adenovirus, cellelinje, samt et farmasoytisk preparat.
FI951138A FI951138A (fi) 1993-07-13 1995-03-10 Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US10/301,085 US20030096787A1 (en) 1993-07-13 2002-11-21 Defective adenovirus vectors and use thereof in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9308596A FR2707664B1 (fr) 1993-07-13 1993-07-13 Vecteurs viraux et utilisation en thérapie génique.

Publications (2)

Publication Number Publication Date
FR2707664A1 FR2707664A1 (fr) 1995-01-20
FR2707664B1 true FR2707664B1 (fr) 1995-09-29

Family

ID=9449205

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9308596A Expired - Fee Related FR2707664B1 (fr) 1993-07-13 1993-07-13 Vecteurs viraux et utilisation en thérapie génique.

Country Status (3)

Country Link
FR (1) FR2707664B1 (fr)
UA (1) UA65516C2 (fr)
ZA (1) ZA945012B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236293B2 (en) 1995-06-15 2012-08-07 Crucell Holland B.V. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012649A2 (fr) * 1992-12-03 1994-06-09 Genzyme Corporation Therapie genique de la fibrose kystique
JPH09500782A (ja) * 1993-04-08 1997-01-28 ジェネティック セラピー，インコーポレイテッド 肺界面活性タンパク質をコード化するｄｎａを含むアデノウイルスベクター
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
FR2724945B1 (fr) * 1994-09-27 1996-12-27 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2738575B1 (fr) * 1995-09-08 1997-10-10 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2741891B1 (fr) * 1995-06-01 1998-01-09 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2729674B1 (fr) * 1995-01-20 1997-04-11 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
FR2737501B1 (fr) 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU752148B2 (en) * 1998-05-27 2002-09-05 Transgene S.A. Chimeric adenoviral vectors
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2254042T3 (es) 2000-03-24 2008-03-16 Biosphere Medical, Inc. Microesferas para embolizacion activa.
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236293B2 (en) 1995-06-15 2012-08-07 Crucell Holland B.V. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer

Also Published As

Publication number Publication date
UA65516C2 (en) 2004-04-15
FR2707664A1 (fr) 1995-01-20
ZA945012B (en) 1995-02-20

Similar Documents

Publication Publication Date Title
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
ZA949104B (en) Recombinant viruses and their use in gene therapy
IL110284A0 (en) Viral vectors and their use in gene therapy
NO943344D0 (no) MN-gen og -protein
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL111682A0 (en) Recombinant viruses and their use in gene therapy
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
FI923911A0 (fi) Dna-molekylers in vitro-syntes.
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
EP0738144A4 (fr) Hexanamides de phenylmethyle et leur utilisation
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
KR950700316A (ko) 재조합 지베렐린 디엔에이(dna) 및 이들의 사용 방법(recombinant gibberellin dna and uses thereof)
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
PH30808A (en) 2-Amino-4-heteroaryl-1,-4-2dihydropyridines and their use in medicaments.
GB9310227D0 (en) Protein and dna
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
AU3698699A (en) Vectors and viruses used in gene therapy
BR7200643U (pt) Disposicao construtiva em caixa sifonada e similares
BR7302167U (pt) Aperfeiçoamento em oxigenador
NO873102L (no) Modifiserte virale glykoproteiner, samt diagnostiske og terapeutiske anvendelser derav.
AU6905298A (en) Defective adenovirus vectors and use thereof in gene therapy
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100331